Brief: Beyondspring Presents Efficacy/Safety Results From A Phase 2 Study Of Pembrolizumab Plus Plinabulin/Docetaxel In Metastatic Nsclc After Progressing On First-Line Immune Checkpoint Inhibitors At Esmo Congress 2024
16/09/2024 12:31
Sept 16 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING PRESENTS EFFICACY/SAFETY RESULTS FROM A PHASE
2
STUDY OF PEMBROLIZUMAB PLUS PLINABULIN/DOCETAXEL IN METASTATIC
NSCLC AFTER PROGRESSING ON FIRST-LINE IMMUNE CHECKPOINT
INHIBITORS AT ESMO CONGRESS 2024
Source text for Eikon: ID:nGNX4mTdDv
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value